ライフサイエンスコーパス: salvage treatment

1 ts who experienced relapse responded well to salvage treatment.

2 dder cancer (MIBC), reserving cystectomy for salvage treatment.

3 specific antigen levels >/= 0.2 ng/mL or any salvage treatment.

4 mechanism, it may offer a fine strategy for salvage treatment.

5 pendymomas located in eloquent areas or as a salvage treatment.

6 loped early disease progression and required salvage treatment.

7 o have isolated local recurrence amenable to salvage treatment.

8 lant (SCT) was compared with chemotherapy as salvage treatment.

9 Patients that relapse require salvage treatment.

10 cutive follow-up visits or the initiation of salvage treatment.

11 tify resistance patterns to select effective salvage treatments.

12 icant advances in supportive care and better salvage treatments.

13 ions unanswered about optimal first-line and salvage treatments.

14 e cancer, including 89 (22%) who received no salvage treatment, 18 (11%) who received salvage radioth

15 success rate with stem-cell transplantation salvage treatment administered among patients in both tr

16 l tolerated and show substantial efficacy as salvage treatment and equal or even superior efficacy co

17 0 NHL patients treated with low-dose TBI and salvage treatment and followed-up for 15 years.

18 ould result in additional neurotoxicity from salvage treatments and brain damage by relapsing tumor.

19 The role of salvage treatments and high-dose chemotherapy at relapse

20 splatin resistance, which requires intensive salvage treatment, and have a 50% risk of cancer-related

21 6 months after chemoradiotherapy can undergo salvage treatment, and their survival is excellent.

22 Purpose No effective salvage treatments are available for patients with advan

23 juvant treatment for all high-risk cases vs. salvage treatment at the time of prostate-specific antig

24 Mastectomies as first salvage treatment for ipsilateral breast tumour recurren

25 SBRT is an effective primary or salvage treatment for mechanically stable spinal metasta

26 d the safety and efficacy of gene therapy as salvage treatment for older XSCID children with inadequa

27 erapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemot

28 The existence of salvage treatment for patients with DLI after TCD alloge

29 matologic effects of single-agent CEP-701 as salvage treatment for patients with refractory, relapsed

30 medicine methods for detecting and planning salvage treatment for prostate cancer local recurrence a

31 Given salvage treatment for recurrent nasopharyngeal carcinoma

32 3/Foxp3 interaction may serve as a potential salvage treatment for recurrent NPC.

33 c survival relative to those who received no salvage treatment (hazard ratio [HR], 0.32 [95% confiden

34 HDCT was the first salvage treatment in 29 patients and second or later sal

35 treatment in 29 patients and second or later salvage treatment in 72 patients.

36 s indicated by the possibility of successful salvage treatment in more than 70% of PET2-positive pati

37 Assessment of dose-intense M-VAC as salvage treatment in patients who failed to respond to t

38 ogenetic abnormalities, sex, and response to salvage treatment is considered, t(8;21) and inv(16) AML

39 Clinically, with such high cure rates after salvage treatments, most of the controversy focuses now

40 ical and/or local recurrence and received no salvage treatment (n = 397), salvage radiotherapy alone

41 de followed by stem cell reinfusion, for the salvage treatment of GCTs.

42 this study were to quantify the prospects of salvage treatment of patients who did not undergo transp

43 Successful salvage treatment of patients who do not undergo transpl

44 HDCT plays an integral role in the salvage treatment of patients with advanced GCTs.

45 pse (LR) and distant metastases (DM) and the salvage treatment of patients with LR only.

46 osurgery has a promising role in primary and salvage treatment of select prostate cancer patients.

47 Radioembolization is a safe and effective salvage treatment option in advanced NET patients with l

48 al fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stab

49 recurrence, or assessment for suitability of salvage treatment or as response assessment within 1-6 m

50 tumor burden that requires intensive ocular-salvage treatment or enucleation.

51 high-dose therapy compared with conventional salvage treatment (OS: 54% v 47%, P = .25; EFS: 53% v 27

52 After salvage treatment, patients with HT had less frequent co

53 irst remission (<12 months vs >/=12 months), salvage treatment phase (first vs second), and age (<55

54 dical prostatectomy or radiation therapy and salvage treatment planning.

55 g trimodality therapy, for whom surveillance/salvage treatment plays a lesser role,(1) in the BMT pop

56 ts, was designed to study the durability of "salvage" treatment regimens.

57 Proton beam therapy as a salvage treatment resulted in high local tumor control r

58 ithin the scope of the increasing use of eye-salvage treatment strategies.

59 l to identify recurrence earlier and perform salvage treatments, thereby possibly improving survival

60 or PET2-positive patients (regardless of the salvage treatment they received) and 81% for PET2-negati

61 wever, the ability to effectively administer salvage treatment to patients with radiorecurrent diseas

62 is has been based on historically controlled salvage treatment trials in patients failing or intolera

63 herapy following incomplete resection, or as salvage treatment upon tumor recurrence.

64 NA-treated patients as a result of effective salvage treatment used for transformed disease.

65 Older patients with relapsed ATRT can have salvage treatment using ICE chemotherapy.

66 apsed after fludarabine therapy responded to salvage treatment, usually with fludarabine-based regime

67 emia who were due to receive first or second salvage treatment were randomly assigned (1:1) via an in

68 agnosis, what are the optimal first-line and salvage treatments, what is the role of maintenance ther

69 Salvage treatment with chemotherapy before DLI can help

70 In patients with a long REM1 (>/=3 years), salvage treatment with either repeat FCR or lenalidomide

71 r patients with AL amyloidosis responding to salvage treatment with pomalidomide.

72 majority of patients eventually relapse, and salvage treatments with non-cross-resistant compounds ar

73 matologic malignancies subsequently received salvage treatment, with either alkylating agents alone (